Gelonghui May 24 丨 Hehuang Pharmaceutical (00013casino50freespins.HK) today announced that it will publish the latest and updated data from several studies of compounds independently developed by Hutchison Pharmaceutical at the 2024 Annual Meeting of the American Society of Clinical Oncology ("ASCO") held in Chicago, Illinois, USA from May 31 to June 4, 2024.
Following the release of preliminary data from the FRUTIGA Phase III study of fruquintinib for the second-line treatment of gastric cancer at the ASCO Plenary Series session held in February 2024casino50freespinsFurther updated efficacy data and quality of life data for key subgroups of the study will be released at this year's ASCO Annual Meeting. In addition, further data from the FRESCO and FRESCO-2 colorectal cancer phase III studies, sufantinib combination therapy in the treatment of small cell lung cancer, and preliminary clinical data from the ERK1/2 inhibitor HMPL-295 will also be announced at the conference.
(: Congratulations